-
Astrazeneca NASDAQ:AZN AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Location: 1 Francis Crick Avenue, Cambridgeshire, CB2 0AA, United Kingdom | Website: https://www.astrazeneca.com/home | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
145.8B
Cash
7.076B
Avg Qtr Burn
N/A
Short % of Float
0.35%
Insider Ownership
0.01%
Institutional Own.
17.03%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Andexxa (andexanet alfa) Details Intracranial haemorrhage | Phase 4 Update | |
Imfinzi (durvalumab) +Imjudo (tremelimumab) +platinum-based chemotherapy Details Cancer, Non-small cell lung carcinoma, Lung cancer | Approved Update | |
Approved Update | ||
Calquence (acalabrutinib) Details Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma | Approved Update | |
Truqap (Capivasertib) + Faslodex (fulvestrant) Details Breast cancer, Cancer | Approved Quarterly sales | |
Voydeya (Danicopan) Details Paroxysmal nocturnal hemoglobinuria | Approved Quarterly sales | |
Approved Quarterly sales | ||
Soliris (eculizumab) Details Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome | Approved Quarterly sales | |
Imfinzi + Lynparza Details Cancer, Solid tumor/s, Endometrial cancer | Approved Quarterly sales | |
Forxiga (dapagliflozin) Details Heart failure | Approved Quarterly sales | |
Imfinzi + chemotherapy (as neoadjuvant treatment) Details Cancer, Non-small cell lung carcinoma, Lung cancer | Approved Quarterly sales | |
Ultomiris Details Rare diseases, Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder (NMOSD) | Approved Quarterly sales | |
Tagrisso Details Lung cancer, Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
Fasenra Details Coronary Microvascular Dysfunction, Eosinophilic granulomatosis with polyangiitis | Approved Quarterly sales | |
Lynparza w/ abiraterone and prednisone or prednisolone Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
Tezspire (tezepelumab) Details no known indication | Approved Quarterly sales | |
Tagrisso + chemotherapy Details Lung cancer, Cancer, EGFR-mutated advanced lung cancer | Approved Quarterly sales | |
Enhertu Details Cancer, Solid tumor/s | Approved Quarterly sales | |
Beyfortus (Nirsevimab) Details Respiratory syncytial virus, Respiratory virus, Viral infection | Approved Quarterly sales | |
Farxiga Details Type 2 diabetes | Approved Quarterly sales | |
Calquence (acalabrutinib) w/ bendamustine and rituximab Details Cancer, Blood cancer, Mantle cell lymphoma | PDUFA Approval decision | |
Enhertu Details Cancer, Breast cancer | PDUFA Approval decision | |
Dato-DXd (Datopotamab deruxtecan) Details Cancer, Non-small cell lung carcinoma, Lung cancer | PDUFA Approval decision | |
Imfinzi (durvalumab) Details Lung cancer, Cancer, Small cell lung cancer | PDUFA Approval decision | |
NDA Submission | ||
Saphnelo Details Idiopathic pulmonary fibrosis | Phase 3 Data readout | |
Orpathys + Tagrisso Details Cancer, Solid tumor/s | Phase 3 Data readout | |
LYNPARZA Details Cancer, Solid tumor/s, Ovarian cancer | Phase 3 Data readout | |
Calquence (acalabrutinib) + venetoclax +/- obinutuzumab Details Cancer, Blood cancer, Chronic lymphocytic leukemia | Phase 3 Data readout | |
Tozorakimab Details Respiratory conditions, Acute respiratory distress syndrome, Lung disease | Phase 3 Data readout | |
Imfinzi (durvalumab) Details Cancer, Non-small cell lung carcinoma, Lung cancer | Phase 3 Data readout | |
LYNPARZA Details Cancer, Solid tumor/s, Ovarian cancer | Phase 3 Data readout | |
Fasenra Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Phase 3 Data readout | ||
Koselugo (selumetinib, MEK inhibitor) Details Cancer, Solid tumor/s, Neurofibromatosis type 1 | Phase 3 Data readout | |
Anselamimab (CAEL-101) Details Amyloid light chain amyloidosis | Phase 3 Data readout | |
Tagrisso Details Cancer, Lung cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Dato-DXd Details Cancer, Breast cancer | Phase 3 Data readout | |
Tezspire (tezepelumab) Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Imfinzi (mono/combo) Details Cancer, Liver cancer | Phase 3 Data readout | |
Imfinzi comb w/ chemotherapy Details Cancer, Gastroesophageal junction tumors, Gastric cancer | Phase 3 Update | |
roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
Phase 3 Update | ||
Sipavibart (AZD3152) Details COVID-19 | Phase 3 Update | |
Imfinzi comb w/ chemotherapy Details Cancer, Biliary Tract Cancer | Phase 3 Update | |
Imfinzi Details Cancer, Bladder cancer | Phase 3 Update | |
Farxiga Details Acute myocardial infarction | Phase 3 Update | |
Fasenra Details Coronary Microvascular Dysfunction | Phase 3 Update | |
Capivasertib Details Breast cancer, Cancer, Triple-negative breast cancer | Phase 3 Update | |
FPI-2265 Details Prostate cancer, Cancer | Phase 2/3 Update | |
balcinrenone/dapagliflozin (MR modulator + SGLT2 inhibitor) Details Cancer, Heart failure, Chronic kidney disease | Phase 2b Data readout | |
Baxdrostat Details Primary aldosteronism | Phase 2 Data readout | |
Baxdrostat Details Pulmonary hypertension | Phase 2 Data readout | |
Baxdrostat Details Chronic kidney disease | Phase 2 Data readout | |
Tozorakimab (IL-33 ligand mAb) Details Diabetic Kidney Disease | Phase 2 Data readout | |
Dato-DXd (Datopotamab deruxtecan) Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 2 Data readout | |
Anselamimab (CAEL-101) Details Amyloid light chain amyloidosis | Phase 2 Data readout | |
Enhertu Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Dato-DXd (Datopotamab deruxtecan) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer | Phase 1/2 Data readout | |
LB-001 Details Methylmalonic acidemia, Genetic disorder, Rare genetic disease | Phase 1/2 Interim update | |
ECC5004 Details Obesity, Type 2 diabetes | Phase 1 Data readout | |
Dato-DXd (Datopotamab deruxtecan) Details Solid tumor/s | Phase 1 Data readout | |
FPI-2068 Details Solid tumor/s, Cancer | Phase 1 Update | |
FPI-2059 Details Solid tumor/s, Cancer | Phase 1 Update | |
Dato-DXd (Datopotamab deruxtecan) Details Non-small cell lung carcinoma, Lung cancer, Cancer | Phase 1 Update | |
FPI-1434 (targeted alpha radioimmunoconjugate) Details Solid tumor/s, Cancer | Phase 1 Update |